| A Trial of Favipiravir in Adults with Mild Coronavirus Disease Covid-19 |
Ongoing |
Favipiravir |
3 |
RC20/220/R |
King Abdulaziz Medical City NG (Riyadh) |
| A National Collaborative Multicenter Phase II Study for Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19 |
Ongoing |
Convalescent Plasma |
2 |
20-COVID-19-01M |
King Fahad Specialist Hospital (Dammam), International Medical Center (Jeddah), King Abdulaziz Medical City NG (Riyadh), King Abdulaziz Medical City NG (Jeddah), King Abdulaziz Hospital NG (Al Ahsa), Prince Mohammad bin Abdulaziz Hospital NG (Medina), Qatif Central Hospital, Dammam Medical Complex, King Fahad Medical City (Riyadh), King Saud Medical City (Riyadh), King Abdullah Medical City (Makkah), Al-Noor Specialist Hospital (Makkah), King Abdullah Medical Complex (Jeddah), Ohud hospital (Medina), King Fahad Genaral Hospital (Medina), Aseer Central Hospital (Abha) |
| An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care |
Ongoing |
• Hydroxychloroquine sulphate• CHLOROQUINE PHOSPHATE• Lopinavir/Ritonavir • Remdesivir• Interferon beta-1b |
3 |
version 8 |
Qatif Central Hospital, Dammam Medical Complex, Ohud hospital (Medina), Al-Noor Specialist Hospital (Makkah), Prince Mohammad bin Abdulaziz hospital (Riyadh) |
| A phase II, multicenter, open label study of treatment escalation to ACVD (Adriamycin, Cyclophosphamide, Vinblastine and Dacarbazine) and Brentuximab-Vedotin in advanced-stage Hodgkin Lymphoma patients with a positive interim PET scan after 2 ABVD cycles (OPTIMIST study) |
Ongoing |
• DOXORUBICIN HYDROCHLORIDE• CYCLOPHOSPHAMIDE• VINBLASTINE SULPHATE • DACARBAZINE• BRENTUXIMAB VEDOTIN |
2 |
RC16/150 |
King Abdulaziz Medical City NG (Riyadh) |
| Phase 3, open label, single arm study to evaluate efficacy and safety of FIX gene transfer with PF-06838435 (rAAV-Spark100-hFIX-Padua) in adult male participants with moderately severe to severe hemophilia B (FIX:C<2%) (BeneGene-2) |
Ongoing |
PF-06838435 |
3 |
C0371002 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of A4250 in Children with Progressive Familial Intrahepatic Cholestasis Types 1 and 2 (PEDFIC 2) |
Ongoing |
A4250 |
3 |
A4250-008 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| "ALL SCTped 2012 FORUMAllogeneic Stem Cell Transplantation in Children and Adolescents with Acute Lymphoblastic Leukaemia" |
Completed |
• BUSULFAN• FLUDARABINE PHOSPHATE• ETOPOSIDE |
3 |
CT17/016/R |
King Abdulaziz Medical City NG (Riyadh) |
| Single arm Phase I/II study of the safety, tolerability and efficacy of the Tocilizumab followed by cisplatin/docetaxel in patients with triple negative locally advanced breast cancer |
Ongoing |
• TOCILIZUMAB (ACTEMRA)• DOCETAXEL (TAXOTERE)• CISPLATIN |
2a |
2181156 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| Re-challenge therapy with chemotherapy and panitumumab in metastatic colorectal cancer patients treated with an anti-EGFR therapy in 1st line treatment: a phase II multicentre study. |
Ongoing |
• PANITUMUMAB• OXALIPLATIN• irinotecan• FLOUROURACIL |
2 |
19-504 |
King Abdullah Medical City (Makkah) |
| An Open-Label, Randomized, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 in Pediatric Subjects Aged 10 to Less Than 18 Years for the Treatment of Relapsing-Remitting Multiple Sclerosis, With Optional Open-Label Extension |
Ongoing |
Interferon beta-1a |
3 |
105MS306 |
King Faisal Specialist Hospital and Research Center (Jeddah), King Khalid University Hospital (Riyadh) |
